Cloud-based Ehave Connect Platform Will Provide Mental Health Practitioners with Comprehensive Network of Multi-Vendor Products to Aid in the Diagnosis and Treatment of Mental Health Conditions
TORONTO, Dec. 14, 2016 /CNW/ -- Multi-Health Systems (MHS), an international healthcare technology developer of scientifically validated assessments, and Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced that the companies have entered into a partnership granting Ehave access to MHS's extensive library of mental health assessments. Under the partnership, MHS's psychological assessment tests will be integrated into Ehave's Ehave Connect mental health digital informatics platform. Initially, the agreement will focus on MHS tests related to behavior and ADHD, including the Conners® suite of ADHD assessments. Additional products from MHS's catalog of mental health assessments and services will be added to Ehave Connect incrementally, following successful integration of the Connors suite.
Once integrated, MHS's Connors ADHD assessments and surveys will be available to mental health practitioners in an entirely digital format, eliminating the need for patients, parents, teachers and clinicians to complete the assessments on paper. The digital administration of assessments will allow clinicians to administer, score and evaluate tests in a streamlined and efficient manner. Once assessments have been completed, results are to be saved in the patient's portal to be referenced at anytime during the patient's treatment, allowing easy comparisons if assessments are readministered to evaluate treatment outcomes. Ehave expects to launch the next generation of Ehave Connect, with MHS assessments incorporated, in Canada and the U.S. in Q1 2017.
"Ehave Connect is an impressive informatics platform that we believe has the potential to enhance the administration and evaluation of our extensive catalog of psychological assessments," commented Hazel Wheldon, President & COO of MHS. "We are excited to work closely with Ehave to launch the next-generation of Ehave Connect with our Connors suite of products and we look forward to integrating additional tests in ADHD and other mental health conditions into Ehave Connect in the future as the platform develops and our partnership expands."
Ehave Connect is a cloud-based, one-stop digital informatics platform intended to provide mental health practitioners with an objective, data-rich network designed to aid in the diagnosis and treatment of mental health disorders. The platform is rapidly expanding to include a plethora of multi-vendor tools covering all aspects of a patient's mental healthcare, including assessments, surveys, digital therapeutics, remediation tools, outcomes tracking, data collection, etc. Ehave Connect will consolidate patient information from multiple publishers into one convenient portal that clinicians, patients and caregivers can access from any computer, tablet or mobile device. Ehave expects Ehave Connect to have broad applicability across mental health and behavioral disorders, and is planning to launch it initially for the assessment, monitoring, management and remediation of ADHD. The user-friendly digital interface of Ehave Connect also offers a robust clinical trial management system that is currently being used to manage and capture clinical data from ongoing studies of Ehave's suite of MegaTeam digital therapeutics for ADHD remediation.
"Patients and their caregivers are often hindered by an outdated and inefficient mental healthcare delivery system. With Ehave Connect, we believe we can modernize the mental healthcare delivery system to enable better treatment decisions across teams and disciplines to improve patient care," commented Prateek Dwivedi, President and CEO of Ehave. "This monumental partnership with MHS allows us to significantly expand our Ehave Connect platform by integrating MHS's scientifically-validated and widely-used Connors assessments, which are the industry's gold standard in behavior assessment. We plan to build upon this flagship agreement by integrating additional products from MHS's vast catalogue of mental health assessments to create a comprehensive mental health informatics platform that can be used by any mental health practitioner to improve the evaluation, diagnosis and treatment of any mental health condition."
About Multi-Health Systems
A leading technology company focused on innovative digital delivery of data analysis and scientifically validated assessments for more than 30 years, Multi-Health Systems Inc. (MHS) serves clients in corporate, clinical, educational, public safety, government, military, pharmaceutical, and research settings. With offices in North America and partners around the world, MHS is dedicated to improving the lives of individuals and communities through technology. MHS has developed leading products such as the Emotional Quotient Inventory (EQ-i 2.0®), the Conners™ suite of ADHD assessments, and the Level of Service™ suite of assessments. MHS has been named one of Canada's Best Managed Companies since 2013. The best managed designation is a recognized symbol of excellence for Canadian businesses. Additionally, in 2016, MHS won Canada's 10 Most Admired Corporate Cultures award in the Growth and Small Cap category. For more information about MHS, please visit www.mhs.com.
About Ehave, Inc.
Ehave is empowering the mental healthcare community with next-generation, data-rich patient management, assessment, and remediation tools. With Ehave Connect, Ehave's cloud-based software platform, clinicians can make better-informed, individualized treatment decisions across teams and disciplines while keeping patients informed and engaged throughout their mental healthcare journey. Ehave Connect offers a powerful set of core features that integrate seamlessly with a growing selection of tools and applications developed by Ehave and its leading partners. Ehave is launching several digital applications under its MegaTeam brand for the assessment and remediation of ADHD, with pilot studies now underway at the Hospital for Sick Children (SickKids). Ehave is headquartered in Toronto's Discovery District, a hub of healthcare, innovation, and technology in Toronto, Canada. For more information, visit https://www.ehave.com/
Forward-Looking Statement Disclaimer
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company's research, manufacturing and other development efforts; (ii) the Company's ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company's products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company's industry and introduction of competing products; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.'s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov
Hazel Wheldon, President and COO
email@example.com; (416) 492-2627 X 246
Danielle Politi, Business Development Manager
Danielle.firstname.lastname@example.org; (416) 492-2627 X 276
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (investors)
email@example.com; (212) 375-2664
Claire LaCagnina (media)
firstname.lastname@example.org; (212) 375-2686
SOURCE Ehave, Inc.